Acute myeloid leukemia (AML) is a blood cancer resulting from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Chemotherapy consisting of cytarabine and anthracyclines has been the standard of AML care for decades, with a 5-year overall survival rate of 25%[1]. Outcomes in older patients, who represent the majority of patients with this disease, are poor with a median survival of 5 to 10 months. Owing to their inability to tolerate intensive chemotherapy, many older patients do not receive any anti-leukemic therapy [2]. Although the development of drugs targeted to specific pathways offers the promise of improved treatment options, resistance to individual inhibitors has limited their effectiveness. This is in part the result of the substantial disease heterogeneity and clonality underlying AML and underscores the need for combinations of targeted therapies to achieve durable responses.